Physician profile
Michael C Tigani
NPI 1548359821
$4,469.33
in general payments reported to CMS, 2019-2025
20 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $390 · 2021: $180 · 2022: $832 · 2023: $322 · 2024: $895 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,739.60 | 2020-2025 | Clareon Panoptix Pro, Tryptyr, Clareon |
| Tarsus Pharmaceuticals, INC. | $734.26 | 2024-2025 | Xdemvy |
| Abbvie INC. | $368.64 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $216.74 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $215.99 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $201.72 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Oyster Point Pharma, INC. | $141.37 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $139.64 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $116.36 | 2020 | |
| Amgen INC. | $107.96 | 2024-2025 | Tepezza |
| Rxsight INC | $94.71 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Dompe US, INC. | $67.52 | 2024-2025 | Oxervate |
| Astellas Pharma US INC | $66.04 | 2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.87 | 2019-2020 | |
| Harrow Eye, LLC | $63.99 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $49.05 | 2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $30.25 | 2022-2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $17.48 | 2024 | Tecnis Iol |
| Horizon Therapeutics Plc | $12.74 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tigani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.